Suggestions
Fabrice Chouraqui
CEO at Cellarity, CEO Partner at Flagship Pioneering
Fabrice Chouraqui is a prominent figure in the pharmaceutical and biotech industries with extensive experience in leadership roles. He currently serves as a Board Member at Orano Med, a company specializing in nuclear medicine.12
Professional Background
Chouraqui holds several key positions:
- CEO-Partner at Flagship Pioneering, a Boston-based biotech investment fund.1
- CEO of Cellarity, a Flagship Pioneering company focused on developing treatments for cellular dysfunction using biology, genomic sequencing, and artificial intelligence.1
Previous Experience
Prior to his current roles, Chouraqui had a distinguished career:
- Worked at Novartis for ten years, including serving as President of Novartis Pharmaceuticals in the USA from 2016 to 2020.1
- Began his career in R&D at Roussel Uclaf and Hoechst Marion Roussel, predecessors to Sanofi.1
- Held management positions in Europe and Asia at Bristol-Myers Squibb.1
Education
Chouraqui has a strong educational background in pharmacy and business:
- MBA from INSEAD (1999)13
- Doctorate in Pharmacy (PharmD) from the University of Paris V1
- Post-Graduate Degree in Quality Management from the University of Paris V1
- M.Sc. in Biological and Medicinal Sciences from the University of Paris V1
Role at Orano Med
As a Board Member at Orano Med, Chouraqui is part of the company's Governing Board, which consists of 8 members with diverse expertise in pharmaceuticals, biotech, and the nuclear sector.2 His experience in the pharmaceutical industry likely provides valuable insights to Orano Med's development in nuclear medicine.
Highlights
“Our problem is not that we aim too high and miss. Our problem is that we aim too low and hit.” This famous quote from Aristotle was referenced during an insightful discussion yesterday between Noubar Afeyan, Founder and CEO Flagship Pioneering and Albert Bourla, CEO Pfizer. It is something that I believe couldn’t be more true.
It’s easy to find comfort in goals you achieve when you set the bar low; however, that isn’t what will push the boundaries of science for the benefit of patients. As leaders, we need to set the bar high and not compromise on our goals to truly make a difference.
#FlagshipJPM #JPM23 #JPM2023 #BioWeekSF #JPMWeek
I look forward to being part of the #LongwoodHealthCareLeaders Webconference and discussing how data can empower the industry to create more impactful medicines. If you’re interested in the conference, here’s more info: https://lnkd.in/ex4kUfKY #AI #artificialintelligence #machinelearning #drugcreation #drugdiscovery #singlecell #medicine #biology Longwood Healthcare Leaders #data #healthcareleaders
